Based on the SELECT-D trial, would you favor rivaroxaban over LMWH for treating cancer-associated VTE in patients with low risk of bleeding?
Community PollStarted
What agent do you prefer to use for treatment of cancer-associated thrombosis in a patient with an average risk of bleeding (no CNS mets, normal renal function, etc)?
160 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Barnes and Jewish Hosp/Washington Univ St Louis
Answered on
Both the SELECT-D trial and the HOKUSAI trial provide evidence that rivaroxaban and edoxaban respectively, have a role in the management of cancer-associated thrombosis (CAT). In addition, an oral presentation from ASH 2018, ADAM VTE trial, also supports a role for consideration of apixaban in the m...
Join for free or sign in to see the full answer